TY - JOUR
T1 - The killer pseudokinase mixed lineage kinase domain-like protein (MLKL)
AU - Murphy, James M.
N1 - Funding Information:
I thank members of my laboratory and col-leagues for discussions, Emma Petrie for critical reading of the manuscript, and collaborators who have contributed to many of the studies described herein. I thank the National Health and Medical Research Council of Australia for funding support (1105754, 1124735, 1124737, and 9000433) and the Victorian State Government Operational Infrastructure Support scheme.
Funding Information:
I thank members of my laboratory and colleagues for discussions, Emma Petrie for critical reading of the manuscript, and collaborators who have contributed to many of the studies described herein. I thank the National Health and Medical Research Council of Australia for funding support (1105754, 1124735, 1124737, and 9000433) and the Victorian State Government Operational Infrastructure Support scheme.
Publisher Copyright:
© 2020 Cold Spring Harbor Laboratory Press; all rights reserved;.
PY - 2020/8
Y1 - 2020/8
N2 - Whereas the apoptosis cell death pathway typically enables cells to undergo death in an immunologically silent manner, cell death by necroptosis induces cell lysis and release of cellular constituents known to elicit an immune response. Consequently, the origins of nec-roptosis likely originated in host defense against pathogens, although recently it has emerged that dysregulation of the pathway underlies many human pathologies. The past decade has seen a rapid advance in our understanding of the molecular mechanisms underlying nec-roptotic cell death, including the implication of the pseudokinase, mixed lineage kinase domain-like protein (MLKL), as the terminal effector in the pathway. Here, I review our current understanding of how MLKL is activated by the upstream receptor interacting protein kinase (RIPK)3, the proposed mechanism(s) by which MLKL kills cells, and recently described layers of regulation that tune MLKL’s killing activity.
AB - Whereas the apoptosis cell death pathway typically enables cells to undergo death in an immunologically silent manner, cell death by necroptosis induces cell lysis and release of cellular constituents known to elicit an immune response. Consequently, the origins of nec-roptosis likely originated in host defense against pathogens, although recently it has emerged that dysregulation of the pathway underlies many human pathologies. The past decade has seen a rapid advance in our understanding of the molecular mechanisms underlying nec-roptotic cell death, including the implication of the pseudokinase, mixed lineage kinase domain-like protein (MLKL), as the terminal effector in the pathway. Here, I review our current understanding of how MLKL is activated by the upstream receptor interacting protein kinase (RIPK)3, the proposed mechanism(s) by which MLKL kills cells, and recently described layers of regulation that tune MLKL’s killing activity.
UR - http://www.scopus.com/inward/record.url?scp=85089129363&partnerID=8YFLogxK
U2 - 10.1101/cshperspect.a036376
DO - 10.1101/cshperspect.a036376
M3 - Article
C2 - 31712266
AN - SCOPUS:85089129363
SN - 1943-0264
VL - 12
JO - Cold Spring Harbor Perspectives in Biology
JF - Cold Spring Harbor Perspectives in Biology
IS - 8
M1 - a036376
ER -